Bright Minds Biosciences Inc. (DRUG) stock
Close on Nov 17, 2026Market cap $156.61MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2025
Valuation
- Market cap
- C$223.26M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Trading
- Previous close
- $22.61
- Open
- $22.22
- Day's range
- $19.86 – $22.48
- Volume
- 181,089
- Average volume (20 days)
- 291,803
- Index membership
- Russell 2000 (since Jun 2025), Russell 3000 (since Aug 2025)
- RSI (14 days)
- 26.5
- Volatility (1 year)
- 86.1%
- Relative volume
- 0.98×
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | DRUG | S&P 500 | Difference | DRUG per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -60.0% | -4.0% | −56.0 pts | ||
| 3 months | -74.2% | -5.0% | −69.2 pts | ||
| Year to date | -73.7% | +8.2% | −82.0 pts | ||
| 1 year | -64.6% | +11.2% | −75.9 pts | ||
| 3 years | +1519.8% | +68.5% | +1451.3 pts | +153.0% | +19.0% |
| 5 years | -16.5% | +67.3% | −83.7 pts | -3.5% | +10.8% |
Eight years at a glance
Fiscal years 2018 to 2025, CAD
EPS, diluted
Press releases
Releases Bright Minds Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Bright Minds Biosciences
Pharmaceutical Preparations
Bright Minds Biosciences Inc. operates as a Canadian biotechnology and pharmaceutical company classified under pharmaceutical preparations. The provided text indicates that the enterprise conducts its activities alongside wholly owned subsidiaries. However, specific operational segments, proprietary therapeutic products or clinical pipeline assets, distinct commercial services, and identified customer groups are not detailed within the excerpted filing text. The entity focuses on administrative, governance, and regulatory compliance functions necessary for maintaining public reporting requirements across relevant capital oversight frameworks.
Company profile, executives and historyBright Minds Biosciences stock: common questions
What is Bright Minds Biosciences's stock price?
DRUG closed at $20.51 on Nov 17, 2026, down 9.29% on the day.
What is Bright Minds Biosciences's market cap?
Bright Minds Biosciences was worth $156.61M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
Does Bright Minds Biosciences pay a dividend?
No. Bright Minds Biosciences has not paid a cash dividend over the last twelve months.
How has DRUG stock performed over the past year?
Including dividends, DRUG returned -64.6% over the past year, against +11.2% for the S&P 500.
Who are Bright Minds Biosciences's competitors?
Companies most similar to Bright Minds Biosciences by business, industry and size include NGEN, MSLE, HELP, CMND, BHST.
See a number that looks wrong?